Clinical Trials Directory
We are doing this study to find the most effective, safe dose of an experimental drug called FG-3246 (the study drug) that is being developed for people with metastatic castration-resistant prostate cancer. We want to know if it is able to shrink the size of tumors and delay the progression of the disease.
We are doing this study to find out if an experimental drug called LY4337713 (the study drug) is a safe and effective option for people who have FAP-positive solid tumors. The study drug is a type of radiotherapy that is intended to target and attach only to FAP. The goal of targeted radiotherapy is to provide selective delivery of radiation doses that can destroy tumor cells.
We are doing this study to understand more about biomarkers (a part of your body) and how they can be used to better diagnose infection. To learn more, please contact us at DukeMESSIStudy@Duke.edu or at 919-452-1605. Estamos haciendo este estudio para entender más sobre biomarcadores (que son parte de su cuerpo) y cómo pueden ser usados estos para diagnosticar infecciones de una mejor manera. Para mayor información, por favor contáctenos al correo DukeMESSIStudy@Duke.edu o al número 919-452-1605.
We are doing this study to learn more about the cause of cardiac (heart) disease or sudden unexplained death, which is something that can run in families. Some conditions that we are looking at are:
- Cardiomyopathies (a disease of the heart muscle that makes it harder for your heart to pump blood to the rest of your body) like hypertrophic cardiomyopathy, dilated cardiomyopathy, or arrhythmogenic cardiomyopathy (also called right ventricular cardiomyopathy)
- Arrhythmia syndromes (a problem with the rate or rhythm of the heartbeat, either too slow or too fast) like long QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, or short QT syndrome
- Sudden cardiac arrest or unexplained sudden death (heart stops suddenly) in someone less than 50 years of age, including sudden infant death syndrome (SIDS)
- Individuals with genetic mutations (variants) in genes that can lead to cardiac disease which include (LMNA, ATP1A3, and TAX1BP3)
We are doing this study to learn more about how genetic variations in people can impact how well different antibody-based drugs work for people who get organ transplants.
In this study, people will answer questions and do simple physical tests three times over six months. They will be randomly placed into one of two groups: one gets coping skills training with a nurse by phone, and the other gets regular care. Everyone will also get a short health check during cancer visits to look for problems like memory loss or falling.